Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
AstraZeneca
Johnson and Johnson
Dow
Colorcon

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR VIVITROL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vivitrol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00156923 ↗ ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults Completed Alkermes, Inc. Phase 3 2003-10-01 This was a Phase 3, multi-center extension of Alkermes' Study ALK21-003EXT (NCT01218971) to further assess the long-term safety of repeat monthly doses of Medisorb® naltrexone (VIVITROL®).
NCT00156936 ↗ ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]) Terminated Alkermes, Inc. Phase 3 2004-08-01 This was a multicenter extension of Alkermes' Study ALK21-006 (NCT01218997) designed to assess the long-term safety of repeat monthly doses of naltrexone long-acting injection. All subjects received open-label Medisorb® naltrexone 380 mg (VIVITROL®). Planned treatment duration was up to 3 years. Alkermes terminated the study for business purposes in December 2006. The median duration of treatment among all subjects in this extension study was 43 weeks.
NCT00338962 ↗ Naltrexone & SSRI in Alcoholics With Depression/PTSD Completed Yale University Phase 3 2001-10-01 The purpose of this study is to evaluate the efficacy of naltrexone in combination with an SSRI to reduce alcohol consumption in alcoholic patients with comorbid PTSD and depression. We hypothesize that the combination of naltrexone and SSRI will exhibit a greater decrease in alcohol consumption than that seen with treatment with SSRI alone, or with a combination of another class of antidepressant and naltrexone. We also hypothesize that SSRI will be effective in treating PTSD and depressive symptoms and naltrexone will be well tolerated.
NCT00476242 ↗ Memantine as a Supplement to Naltrexone in Treating Heroin Dependence Completed National Institute on Drug Abuse (NIDA) Phase 2/Phase 3 2008-06-01 Prospective participants will undergo a screening process at the clinic to determine eligibility. After screening, eligible patients will complete an 8-day inpatient detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg bid. Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month (the total of three injections) while memantine or placebo will be taken daily. In addition, patients will receive twice weekly psychosocial intervention that will include motivational interviewing and cognitive-behavioral relapse prevention. The outpatient treatment will also consist of 3 weekly visits to the clinic in which patients will receive counseling to help maintain abstinence and improve compliance with study medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vivitrol

Condition Name

Condition Name for Vivitrol
Intervention Trials
Opiate Dependence 11
Alcohol Dependence 11
Opioid-use Disorder 10
Opioid Dependence 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vivitrol
Intervention Trials
Opioid-Related Disorders 43
Alcoholism 22
Disease 11
Substance-Related Disorders 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vivitrol

Trials by Country

Trials by Country for Vivitrol
Location Trials
United States 126
Norway 6
Russian Federation 3
Canada 2
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vivitrol
Location Trials
New York 26
California 11
Maryland 9
Pennsylvania 8
Connecticut 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vivitrol

Clinical Trial Phase

Clinical Trial Phase for Vivitrol
Clinical Trial Phase Trials
Phase 4 19
Phase 3 21
Phase 2/Phase 3 8
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vivitrol
Clinical Trial Phase Trials
Completed 58
Recruiting 9
Not yet recruiting 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vivitrol

Sponsor Name

Sponsor Name for Vivitrol
Sponsor Trials
National Institute on Drug Abuse (NIDA) 30
Alkermes, Inc. 24
New York State Psychiatric Institute 13
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vivitrol
Sponsor Trials
Other 115
Industry 38
NIH 36
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Harvard Business School
Johnson and Johnson
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.